{"id":"W4387782335","doi":"10.1038/s41591-023-02593-0","title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"ca_institutions":"Zymeworks (Canada)","funders":"MacroGenics; NRG Oncology","keywords":"Medicine; Internal medicine; Refractory (planetary science); Adverse effect; Clinical endpoint; Cancer; Clinical trial; Oncology; Cohort; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001050262,0.0001927268,0.0004643425,0.0002092113,0.0001605317,0.0000189498,0.00008979069,0.0002104591,0.0000470923],"category_scores_gemma":[0.0006324561,0.0001083282,0.00004408598,0.0007414938,0.0003874393,0.00003721695,0.00004159823,0.0006619942,0.000002806091],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001047621,"about_ca_system_score_gemma":0.0001098044,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001420164,"about_ca_topic_score_gemma":0.0001160861,"domain_scores_codex":[0.9985028,0.00006880321,0.0004030667,0.0003361281,0.0003281593,0.0003610647],"domain_scores_gemma":[0.9991981,0.0003211028,0.0001108498,0.0002126903,0.00005204065,0.000105236],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3405977,0.0005033214,0.004208955,0.0009850379,0.0006740143,0.00382288,0.009723984,0.000004166434,0.3099998,0.0009331512,0.1596342,0.1689128],"study_design_scores_gemma":[0.7061995,0.01204706,0.01840319,0.004263707,0.0004208111,0.001254703,0.01884198,0.003735874,0.02407148,0.001440702,0.2081497,0.001171293],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9386845,0.04383503,0.000004310853,0.0153086,0.0005938439,0.0007678158,0.00000571517,0.00008551353,0.0007146971],"genre_scores_gemma":[0.9907062,0.006900171,0.00003410398,0.001374412,0.0005420368,0.00005401722,0.00003183024,0.00002234662,0.0003348569],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3656017,"threshold_uncertainty_score":0.4417495,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0182040159186513,"score_gpt":0.3508122363939516,"score_spread":0.3326082204753003,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}